The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The European regulator will conduct a re-inspection of the facility to verify the compliance
Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
ANVIMO will be available in dosages of 240 mg and 480 mg
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Subscribe To Our Newsletter & Stay Updated
